Radosław Polański

1.9k total citations
14 papers, 602 citations indexed

About

Radosław Polański is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Radosław Polański has authored 14 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Organic Chemistry. Recurrent topics in Radosław Polański's work include Cancer-related Molecular Pathways (5 papers), Epigenetics and DNA Methylation (4 papers) and Ubiquitin and proteasome pathways (3 papers). Radosław Polański is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Epigenetics and DNA Methylation (4 papers) and Ubiquitin and proteasome pathways (3 papers). Radosław Polański collaborates with scholars based in United Kingdom, United States and Japan. Radosław Polański's co-authors include Nikolina Vlatković, Mark T. Boyd, Christopher J. Morrow, Susan E. Critchlow, Daisuke Nonaka, Cassandra L. Hodgkinson, Paul A. Kelly, Francesca Trapani, Paul D. Smith and Alberto Fusi and has published in prestigious journals such as Cancer, Cancer Research and Clinical Cancer Research.

In The Last Decade

Radosław Polański

14 papers receiving 596 citations

Peers

Countries citing papers authored by Radosław Polański

Since Specialization

Citations

This map shows the geographic impact of Radosław Polański's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radosław Polański with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radosław Polański more than expected).

Fields of papers citing papers by Radosław Polański

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Radosław Polański. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radosław Polański. The network helps show where Radosław Polański may publish in the future.

Co-authorship network of co-authors of Radosław Polański

This figure shows the co-authorship network connecting the top 25 collaborators of Radosław Polański. A scholar is included among the top collaborators of Radosław Polański based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radosław Polański. Radosław Polański is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Accelerating the Validation of Endogenous On-Target Engagement and In Cellulo Kinetic Assessment for Covalent Inhibitors of KRAS ^G12C in Early Drug Discovery 2022 ·ACS Chemical Biology ·Vasudev Kantae, Radosław Polański, Hilary Lewis, Afreen Haider, Derek Barratt, Bharath Srinivasan	6
2	Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD) 2020 ·Cancer Research ·James S. Scott, Tom Moss, (unknown), (unknown), Christopher J. Morrow, Mandy Lawson, (unknown), Eric T. Gangl, Pablo Morentin Gutierrez, (unknown), Justin P.O. Lindemann, Andrew Sykes, David I. Fisher, Radosław Polański, Danielle Carroll, (unknown), Teresa Klinowska	11
3	Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833 2020 ·ACS Medicinal Chemistry Letters ·James S. Scott, Tom Moss, Bernard Barlaam, Paul R. J. Davey, Gary Fairley, Eric T. Gangl, Ryan Greenwood, Holia Hatoum‐Mokdad, (unknown), (unknown), Radosław Polański, S.P. Stokes, Michael Tucker, Jeffrey Varnes, Bin Yang	12
4	Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists 2019 ·Journal of Medicinal Chemistry ·James S. Scott, Andrew Bailey, David Buttar, Rodrigo J. Carbajo, Jon Curwen, Paul R. J. Davey, Robert D. M. Davies, Sébastien L. Degorce, Craig S. Donald, Eric T. Gangl, Ryan Greenwood, Sam D. Groombridge, Tony Johnson, Scott G. Lamont, Mandy Lawson, (unknown), Christopher J. Morrow, Tom Moss, Jennifer H. Pink, Radosław Polański	26
5	Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry 2019 ·ACS Medicinal Chemistry Letters ·James S. Scott, J. Breed, Rodrigo J. Carbajo, Paul R. J. Davey, Ryan Greenwood, Hoan K. Huynh, Teresa Klinowska, Christopher J. Morrow, Tom Moss, Radosław Polański, J. Willem M. Nissink, Jeffrey Varnes, Bin Yang	7
6	Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors 2018 ·Molecular Cancer Therapeutics ·James T. Lynch, Urszula M. Polanska, (unknown), Oona Delpuech, Juliana Maynard, (unknown), Catherine A. Eberlein, Carol Lenaghan, Radosław Polański, Alvaro Avivar‐Valderas, Marie Cumberbatch, Teresa Klinowska, Susan E. Critchlow, Francisco Cruzalegui, Simon T. Barry	18
7	Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines 2015 ·Cell Death and Disease ·Radosław Polański, (unknown), Urszula M. Polanska, Tudor Petreuş, Eric Tang	21
8	Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism 2014 ·Cancer Letters ·Radosław Polański, Aidan P. Noon, Jeremy P. Blaydes, (unknown), Carlos P. Rubbi, Keith Parsons, Nikolina Vlatković, Mark T. Boyd	18
9	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer 2013 ·Clinical Cancer Research ·Radosław Polański, Cassandra L. Hodgkinson, Alberto Fusi, Daisuke Nonaka, Lynsey Priest, Paul A. Kelly, Francesca Trapani, Paul Bishop, Anne White, Susan E. Critchlow, Paul D. Smith, Fiona Blackhall, Caroline Dive, Christopher J. Morrow	282
10	Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy 2011 ·British Journal of Urology ·Aidan P. Noon, Radosław Polański, (unknown), Helen Kalirai, (unknown), Fiona Campbell, (unknown), Richard Eccles, Bryony H. Lloyd, D. Ross Sibson, Sarah E. Coupland, Sarah L. Lake, Keith Parsons, Nikolina Vlatković, Mark T. Boyd	28
11	MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility 2011 ·Carcinogenesis ·Radosław Polański, (unknown), (unknown), Rosalind E. Jenkins, (unknown), (unknown), (unknown), (unknown), Carlos P. Rubbi, Nikolina Vlatković, Mark T. Boyd	23
12	MDM2 promotes cell motility and invasiveness through a RING‐finger independent mechanism 2010 ·FEBS Letters ·Radosław Polański, (unknown), (unknown), (unknown), Hubert Pakula, Carlos P. Rubbi, Nikolina Vlatković, Mark T. Boyd	20
13	p53 and MDM2 in renal cell carcinoma 2010 ·Cancer ·Aidan P. Noon, Nikolina Vlatković, Radosław Polański, (unknown), (unknown), Keith Parsons, Mark T. Boyd	85
14	MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination 2008 ·Cancer Research ·(unknown), (unknown), (unknown), Rosalind E. Jenkins, (unknown), Radosław Polański, Nikolina Vlatković, Mark T. Boyd	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact